ICU Medical, Inc. (ICUI)
| Market Cap | 4.31B |
| Revenue (ttm) | 1.26B |
| Net Income (ttm) | 93.77M |
| Shares Out | 21.15M |
| EPS (ttm) | 4.33 |
| PE Ratio | 47.88 |
| Forward PE | 29.50 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 21 |
| Last Price | $207.27 |
| Previous Close | $203.14 |
| Change ($) | 4.13 |
| Change (%) | 2.03% |
| Day's Open | 204.11 |
| Day's Range | 202.48 - 207.83 |
| Day's Volume | 24,934 |
| 52-Week Range | 170.57 - 227.07 |
ICU Medical (ICUI) delivered earnings and revenue surprises of 5.88% and 4.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN CLEMENTE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and crit...
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As bond yields pop and the rotation out of tech into recovery plays continues, Q.ai's Artificial Intelligence has brought you today's top buys.
SAN CLEMENTE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and cri...
SAN CLEMENTE, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and cri...
SAN CLEMENTE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and cri...
This medical device company is a vital part of the backbone of hospital products utilized in the U.S. and around the world.
ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q3 2020 Results - Earnings Call Transcript
ICU Medical (ICUI) delivered earnings and revenue surprises of 48.44% and 13.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN CLEMENTE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and cri...
SAN CLEMENTE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and ...
ICU Medical (ICUI) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q2 2020 Results - Earnings Call Transcript
SAN CLEMENTE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and c...
SAN CLEMENTE, Calif., Aug. 10, 2020 /PRNewswire/ -- ICU Medical Inc.
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN CLEMENTE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and c...
NEW YORK, June 2, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ICU Medical, Inc. ("ICU" or "the Company") ...
ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q1 2020 Results - Earnings Call Transcript
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q4 2019 Results - Earnings Call Transcript
ICU Medical (ICUI) delivered earnings and revenue surprises of 19.75% and 6.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical, Inc (ICUI) CEO Vivek Jain on Q3 2019 Results - Earnings Call Transcript
ICU Medical (ICUI) delivered earnings and revenue surprises of 1.85% and 6.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN CLEMENTE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and ...
ICU Medical, Inc. (ICUI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q2 2019 Results - Earnings Call Transcript
ICU Medical (ICUI) delivered earnings and revenue surprises of -4.78% and 1.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical, Inc. (ICUI) CEO Vivek Jain on Q1 2019 Results - Earnings Call Transcript
ICU Medical (ICUI) delivered earnings and revenue surprises of 18.35% and 4.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) could produce exceptional returns because of its solid growth attributes.
About ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana h... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Mar 31, 1992 |
| CEO Vivek Jain | Employees 7,900 |
| Stock Exchange NASDAQ | Ticker Symbol ICUI |
Financial Performance
In 2020, ICU Medical's revenue was $1.27 billion, an increase of 0.38% compared to the previous year's $1.27 billion. Earnings were $86.87 million, a decrease of -14.02%.
Analyst Forecasts
According to 4 analysts, the average rating for ICU Medical stock is "Buy." The 12-month stock price forecast is 240.33, which is an increase of 15.95% from the latest price.